Limits upfront costs for oral anticancer medications for persons covered under certain health benefits plans.
Impact
If enacted, this bill would significantly alter the financial landscape for patients undergoing cancer treatment, particularly for those relying on oral medications. Many patients face financial barriers due to the high costs associated with these therapies, often needing to front substantial amounts before obtaining reimbursements from insurers. A2464 seeks to alleviate these burdens by ensuring that coverage conditions for oral medications are equal to those for intravenous alternatives, thus reducing the economic strain on patients.
Summary
Assembly Bill A2464 aims to limit the upfront costs that patients need to pay for orally administered anticancer medications under certain health benefits plans in New Jersey. The bill mandates that health insurers provide coverage for these medications under terms no less favorable than what is available for intravenously administered or injected anticancer medications. Specifically, it requires that no patient be subjected to additional upfront costs beyond their standard copayment, deductible, or coinsurance when obtaining these medications, even if reimbursement for any costs is later provided.
Contention
The bill's introduction may spark discussions regarding healthcare equity and the financial responsibilities of patients versus insurance providers. Critics may argue that while the intent is to provide relief, the increased responsibility placed on insurers could lead to higher premiums across the board, affecting all policyholders. Additionally, there could be concerns regarding the need for oversight of how insurers implement these changes and ensure compliance with the new requirements. Balancing patient care costs with the financial implications for health plans will be critical in the ongoing discourse surrounding this legislation.
Prohibits SHBP, SEHBP, and Medicaid from denying coverage for maintenance medications for chronic conditions for covered persons solely because of change in health benefits plan or pharmacy benefits manager.
Prohibits SHBP, SEHBP, and Medicaid from denying coverage for maintenance medications for chronic conditions for covered persons solely because of change in health benefits plan or pharmacy benefits manager.
Requires health care practitioners prescribing opioid medications to limit amount of prescribed medication to seven-day supply, except in certain circumstances.